Page last updated: 2024-11-13

naloxone-3-glucuronide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

naloxone-3-glucuronide: main metabolite of naloxone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71311610
MeSH IDM0508329

Synonyms (14)

Synonym
naloxone-3-glucuronide
22135-79-1
.beta.-d-glucopyranosiduronic acid, (5.alpha.)-4,5-epoxy-14-hydroxy-6-oxo-17-(2-propenyl)morphinan-3-yl
naloxone 3-b-d-glucuronide
W-201919
unii-86o922u8j0
86o922u8j0 ,
beta-d-glucopyranosiduronic acid, (5alpha)-4,5-epoxy-14-hydroxy-6-oxo-17-(2-propenyl)morphinan-3-yl
naloxone 3-o-beta-d glucuronide
Q27269752
(2s,3s,4s,5r,6s)-6-[[(4r,4as,7ar,12bs)-4a-hydroxy-7-oxo-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
naloxone 3-?-d-glucuronide
naloxone-3-beta-d-glucuronide
naloxone-3-beta-d-glucuronide, 1mg/ml in methanol/water : 1/1

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The aim of this paper was to report the pharmacokinetic results from a single-dose study and a multiple-dose bioequivalence study of OXN versus separate formulations of oxycodone PR and naloxone PR administered concurrently in healthy subjects."( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008
)
0.35
" The pharmacokinetic properties of the OXN FDC were similar to those of oxycodone PR + naloxone PR given as separate formulations, based on the regulatory definition."( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008
)
0.35
"We analysed samples from three pharmacokinetic studies to determine the serum concentrations of naloxone-3-glucuronide (N3G), the main metabolite of naloxone, with or without exposure to remifentanil."( The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.
Dale, O; Skarra, S; Skulberg, AK; Tylleskar, I, 2021
)
0.84
" The dose-corrected Cmax of N3G after intranasal administration of naloxone under remifentanil exposure was significantly lower (4."( The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.
Dale, O; Skarra, S; Skulberg, AK; Tylleskar, I, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" Treatments were considered bioequivalent if the 90% CIs for relative bioavailability calculations fell within a predetermined range of 80% to 125%."( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008
)
0.35
" These findings suggest that the coadministration of oxycodone PR and naloxone PR in an FDC would not significantly affect the bioavailability of either of its constituents in these subjects."( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008
)
0.35
"Remifentanil has been shown to increase the bioavailability of nasally administered naloxone."( The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.
Dale, O; Skarra, S; Skulberg, AK; Tylleskar, I, 2021
)
0.62
"Remifentanil increases the bioavailability of naloxone after nasal administration by reducing the pre-systemic metabolism of the swallowed part of the nasal dose."( The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.
Dale, O; Skarra, S; Skulberg, AK; Tylleskar, I, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.02 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (33.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]